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Background:
In an earlier study, intravenous (i.v.) iban dronate 6 mg administered every 3-4 weeks had a similarly good renal safety profile whether infused over 15 or 60 min in women with breast cancer and bone metastases. This current study focuses on the renal safety of the extended use of ibandronate. Patients and Methods: Patients completing the original study could choose to enter a followup phase and continue (or switch) to receive ibandronate 6 mg by 15min i.v. infu sion every 3-4 weeks. The primary endpoint was the per centage of patients with a serum creatinine increase of ≥44.2 mmol/l (= 0.5 mg/dl) from core baseline. Results: Fourteen patients entered the followup phase and re ceived a median of 16 infusions (range: [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . No patient reached the primary endpoint. Most adverse events were mild to moderate in intensity. None of the 6 re ported treatmentrelated adverse events was considered severe or reported as a serious adverse event. Conclusions: Ibandronate was well tolerated when adminis tered as a 6mg i.v. infusion over 15 min every 3-4 weeks during the followup phase to the earlier core study. No evidence of any treatmentrelated deterioration in renal function was noted, and no new or unexpected adverse events occurred.
Introduction
Bisphosphonates are standard treatment to prevent skeletal complications of bone metastases [1, 2] . In patients with metas tatic breast cancer, the American Society of Clinical Oncologyguidelinesrecommendstartingbisphosphonatesat thetimeofdiagnosisofradiologicallyconfirmedbonemetastases,andtocontinuethistreatmentuntilthereisasubstantial decline in performance status [3] . Ibandronate, a nitrogencontainingbisphosphonate,isindicatedforthepreventionof skeletal-relatedeventsinpatientswithbreastcancerandbone metastases [4] .Studiesofibandronate6mgintravenous(i.v.) have demonstrated significantly reduced skeletal morbidity periodrates(numberof12-weekperiodswithnewboneevents) compared with placebo (p = 0.004), decreases in bone pain scoresandanalgesicuse,andanimprovedqualityoflife [5] [6] [7] . Some nitrogen-containing bisphosphonates are associated withanincreasedriskofrenaltoxicity,especiallyafterrapid i.v.infusion [8] [9] [10] [11] [12] [13] .Intwodouble-blind,randomizedphaseIII studiescomparingzoledronicacidwithdenosumab,renalfailure wasreportedin2.5%ofpatientswithbreast cancer [14] and in 2.8% of patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [15] receiving zoledronicacid.Astudyoftheeffectonrenalfunctionofrepeated15-mininfusionsofibandronate6mginwomenwith breastcancerandbonemetastaseswascompletedin10centers inAustria,7centersinSwitzerland,and1centerinGermany [16] .Patientsreceivedibandronate6mgi.v.eitherasa15-min infusion(n=102)ora60-mininfusion(n=28)every3or4 weeksfor6months.The60-minarmwasregardedasthecontrol arm. The results showed that ibandronate administered over15minwaswelltoleratedwithasafetyprofileconsistent with that of the 60-min infusion. No evidence for any treatment-relateddeteriorationinrenalfunctionwasseen,asassessedbythechangefrombaselineinserumcreatinine,calculat ed creatinineclearance,orintheurinaryexcretionofmarkersof glomerularandtubularfunction.Afterthecompletionofthe 6-monthcoretrial,patientsenrolledintheSwisscenterswere giventheoptiontoenterafollow-upphaseuntilreimbursement.Patientscouldchooseeithertocontinuetreatmentwith the15-mininfusionofi.v.ibandronateevery3or4weeksor toswitchtooralibandronate(50mgtabletsdaily).Theobjectiveofthefollow-upphasewastocontinuetoinvestigatethe safety and tolerability of 15-min i.v. ibandronate infusions, withspecialfocusonnephrotoxicity.Patientsoptingfororal ibandronatewerenotfollowedafterthefinalvisitofthecore trial.Todate,thisisthefirstpublishedlong-termprospective studyofibandronatewithaprimaryendpointofrenalsafety. 
Patients and Methods

Study Design
Assessments
Blood samples for the assessment of serum creatinine and calculated creatinineclearance(Cockcroft-Gaultformula)weretakenateachstudy visit(visits8-14).Routineurinalysislaboratorytests(a-2-macroglobulin, immunoglobulinG,transferrin,albumin,a-1-microglobulin,retinol-bindingprotein,totalprotein,creatinine,monoclonalfreelightchains(BenceJones protein), and dipstick results of erythrocytes, leucocytes, and nitrite) were performed at each scheduled visit, and vital signs (blood pressure, pulse, weight, body mass index, and body temperature) were assessed at visits 12 and 14. Blood and urine tests were performed at a central laboratory, but, unlike in the core phase of the trial, the results werenotrequiredbeforethenextinfusion.Adverseevents(AEs)were monitoredthroughoutthestudy.
Endpoints
Asinthecorestudy,theprimaryendpointwasthepercentageofpatients with a serum creatinine increase of ≥ 44.2 mmol/l (= 0.5 mg/dl) from baseline.
Statistical Analysis
Continuousdataweresummarizedbymean,standarddeviation,median, andrange(minimum,maximum).Categoricaldatawerepresentedusing absoluteandrelativefrequencies.
Results
Two of 7 Swiss centers participated in the follow-up phase. These 2 sites had enrolled 27 patients in the core study (15-min arm: 23 patients; 60-min arm: 4 patients). Of the 22/27 patients who completed the 6-month core trial, 14 were enrolled into the follow-up phase. 13 of the 14 patients continued with the 15-min i.v. infusion to which they had been randomized at study entry, and 1 patient switched fromthe60-mini.v.infusionarmtotheibandronate15-min i.v. infusion( fig.1) patients(29%)experienced4grade3(severe)AEs:sicksinus syndrome (also reported as a serious grade 3 AE), venous thrombosis,lossofappetite,andbonepain.Anotherpatient (inadditiontothepatientwithsicksinussyndrome)reported a serious AE: a mild worsening of her general condition. NeitherseriousAEwasconsideredbytheinvestigatortobe related to study therapy, and both conditions improved followingtheirtreatment.SixAEsreportedin3patients(21%) were considered by the investigator to be treatment-related althoughnonewasconsideredsevereorreportedasaserious AE.Nopatientdiedduringthefollow-upphase.Noclinically relevant changes from baseline in vital signs were reported duringthefollow-upstudy.
Renal Function
Noneofthe14patientsincludedinthefollow-upphasemet thecriteriaforanincreasefrombaselineinserumcreatinine of≥44.2mmol/l.Noobviousrelationshipbetweenthenumber ofibandronateinfusionsandeitherserumcreatininelevelsor the change from baseline in serum creatinine was observed; both remained relatively stable throughout the core study andfollow-upperiod( fig.2 ).Forpatientsenrolledinthefollow-upphase,themeanbaselineserumcreatininevaluewas 59.4 ± 10.6 mmol/l, and the mean baseline calculated creatinine clearance was 93.5 ± 28.5 ml/min ( fig. 3) . No clinically relevant change from baseline in either parameter was observedoverthecourseofthetrial:changesofbetween1.3and -10.6 mmol/l for mean serum creatinine values and between 17.3and-1.8ml/minforcalculatedcreatinineclearancewere observed ( fig. 3) . No clinically relevant urinalysis findings werenotedduringthefollow-upphase.
Adverse Events
All 14 patients reported at least 1 AE during the follow-up phase. Arthralgia and nausea were reported by 5 patients (36%) and were the most commonly reported AEs. Fatigue wasreportedby4patients(29%),andbonepain,paresthesia, nasopharyngitis, and cough by 3 patients (21%) each. Two patients(14%)reportedmusculoskeletalchestpain,extremity pain, anorexia, vomiting, and toothache. The majority of AEs were mild or moderate (grade 1/2) in intensity. Four [18, 19] and a growing body of other evidence suggesting that ibandronatehasnegligiblenephrotoxicityandprobablyabetter renal safety profile than other i.v. bisphosphonates [20] . Thisimprovedrenaltolerabilitymaybelinkedtodifferences inproteinbindingandrenaltissuehalf-life [17] .Ongoingexperienceintheuseoftheregimeninreal-lifeclinicalpractice willaddtothisaccumulatingdata.
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